Bernardo Cacho-Díaz1, Héctor Spínola-Maroño2, Laura G Mendoza-Olivas2, Myrna Candelaria3. 1. Neuro-oncology Unit, Instituto Nacional de Cancerología, Av. San Fernando 22. Col. Sección XVI. Tlalpan, ZC 14080, Mexico City, Mexico. bernardocacho@doctor.com. 2. Neuro-oncology Unit, Instituto Nacional de Cancerología, Av. San Fernando 22. Col. Sección XVI. Tlalpan, ZC 14080, Mexico City, Mexico. 3. Research Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Abstract
INTRODUCTION: Cerebrovascular disease (CVD) and cancer are among the most common causes of mortality worldwide, preceded only by ischemic heart disease (IHD). Thrombocytopenia was shown to be associated with poor outcomes in IHD and CVD in the general population. This study aimed to assess the relationship of thrombocytopenia with poor outcomes in cancer patients with CVD. MATERIALS AND METHODS: Data on patients with concomitant CVD and cancer who were initially treated at a cancer referral center between January 2010 and December 2017 were included. Thrombocytopenia was defined as a platelet count < 150,000/mm3 during the first 24 h of CVD symptom onset. The IRB (CI/837/17) approved the review of clinical records. RESULTS: Among 268 cancer patients with CVD included in the study, 210 met the inclusion criteria. Median overall survival of the entire cohort was 7.2 months, which was significantly shorter in males (p = 0.029) and patients with hematologic tumors (p = 0.009), hemorrhagic CVD (p < 0.001), altered mental status (p < 0.001), and thrombocytopenia (p < 0.001). Multiple regression logistic analysis revealed that thrombocytopenia (risk ratio [RR] 1.6, 95% confidence interval [CI] 1.1-2.4) and altered mental status (RR 2.7, 95% CI 1.9-4.0) remained statistically significant risk factors for mortality. CONCLUSION: In cancer patients with CVD, thrombocytopenia at the time of CVD diagnosis and altered mental status during initial clinical evaluation were associated with higher mortality, which should be confirmed in future studies.
INTRODUCTION:Cerebrovascular disease (CVD) and cancer are among the most common causes of mortality worldwide, preceded only by ischemic heart disease (IHD). Thrombocytopenia was shown to be associated with poor outcomes in IHD and CVD in the general population. This study aimed to assess the relationship of thrombocytopenia with poor outcomes in cancerpatients with CVD. MATERIALS AND METHODS: Data on patients with concomitant CVD and cancer who were initially treated at a cancer referral center between January 2010 and December 2017 were included. Thrombocytopenia was defined as a platelet count < 150,000/mm3 during the first 24 h of CVD symptom onset. The IRB (CI/837/17) approved the review of clinical records. RESULTS: Among 268 cancerpatients with CVD included in the study, 210 met the inclusion criteria. Median overall survival of the entire cohort was 7.2 months, which was significantly shorter in males (p = 0.029) and patients with hematologic tumors (p = 0.009), hemorrhagic CVD (p < 0.001), altered mental status (p < 0.001), and thrombocytopenia (p < 0.001). Multiple regression logistic analysis revealed that thrombocytopenia (risk ratio [RR] 1.6, 95% confidence interval [CI] 1.1-2.4) and altered mental status (RR 2.7, 95% CI 1.9-4.0) remained statistically significant risk factors for mortality. CONCLUSION: In cancerpatients with CVD, thrombocytopenia at the time of CVD diagnosis and altered mental status during initial clinical evaluation were associated with higher mortality, which should be confirmed in future studies.
Authors: Amit N Vora; Michael Chenier; Phillip J Schulte; Shaun Goodman; Eric D Peterson; Karen Pieper; Marc E Jolicoeur; Kenneth W Mahaffey; Harvey White; Tracy Y Wang Journal: Am Heart J Date: 2014-04-24 Impact factor: 4.749
Authors: Yun Yun Zhang; Dennis Cordato; Qing Shen; Ai Zhen Sheng; Wai Tak Hung; Daniel K Y Chan Journal: Cerebrovasc Dis Date: 2006-12-01 Impact factor: 2.762
Authors: M W McClure; S D Berkowitz; R Sparapani; R Tuttle; N S Kleiman; L G Berdan; A M Lincoff; J Deckers; R Diaz; K R Karsch; D Gretler; M Kitt; M Simoons; E J Topol; R M Califf; R A Harrington Journal: Circulation Date: 1999-06-08 Impact factor: 29.690
Authors: Jason J Sico; Michael S Phipps; John Concato; Carolyn K Wells; Albert C Lo; Steven E Nadeau; Linda S Williams; Aldo J Peixoto; Mark Gorman; John L Boice; Dawn M Bravata Journal: J Stroke Cerebrovasc Dis Date: 2012-09-10 Impact factor: 2.136
Authors: Oh Young Bang; Jin Myoung Seok; Seon Gyeong Kim; Ji Man Hong; Hahn Young Kim; Jun Lee; Pil-Wook Chung; Kwang-Yeol Park; Gyeong-Moon Kim; Chin-Sang Chung; Kwang Ho Lee Journal: J Clin Neurol Date: 2011-06-28 Impact factor: 3.077
Authors: Kristin Wallace; Hong Li; J Grant Brazeal; David N Lewin; Shaoli Sun; Aissatou Ba; Chrystal M Paulos; Saleh Rachidi; Zihai Li; Alexander V Alekseyenko Journal: Cancer Epidemiol Date: 2020-06-07 Impact factor: 2.984
Authors: Babak B Navi; Cenai Zhang; Carla P Sherman; Richard Genova; Natalie M LeMoss; Hooman Kamel; Scott T Tagawa; Ashish Saxena; Allyson J Ocean; Scott E Kasner; Mary Cushman; Mitchell S V Elkind; Ellinor Peerschke; Lisa M DeAngelis Journal: J Thromb Haemost Date: 2022-06-21 Impact factor: 16.036